DIAGNOS and the third largest optical retailer in Costa Rica Piloting CARA and its Telemedicine technology
March 04 2021 - 9:41AM
Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces today the signing of a contract with
Óptica Central, the third largest optical chain store in Costa Rica
for implementation of CARA across Costa Rica.
“Óptica Central, in collaboration with Aselcom,
DIAGNOS’ distributor, are pleased to start screening the population
across our optical stores by providing DIAGNOS’ proven AI solution
for early detection of eye illnesses, such as Diabetic Retinopathy,
as well as preventing blindness caused by diabetes.
There is no doubt that DIAGNOS’ experience in Costa Rica, and in
other Latin American countries, has been at the forefront in
proving its service with their remarkable technology,” said
Mr. Jefrey Salas, CEO of Óptica
Central.
“At DIAGNOS we have made our mark in different
parts of the world, in collaboration with our partners and
different stakeholders, where our AI technology and experience for
serving patients has set the standard. We know that Diabetic
Retinopathy has become the main cause of blindness worldwide
occurring in patients aged 20-64 years. Costa Rica is no different
from other countries, with almost 15% of its population over 20
having diabetes, with less than 11% diagnosed. At least 35% have
been identified with Diabetic Retinopathy within the diabetic
population and 10% are in jeopardy of having severe retinopathy
that will affect their vision. Our technology is helping now,
through Óptica Central, to fill this gap,” said Mr. Andre
Larente, President of DIAGNOS.
About Óptica CentralFounded in July 1983, Óptica
Central, located in Alajuela, has become a pioneer in the visual
health service offering optics and optometry services. Since its
inception, it has been contributing to the visual health of the
population with affordable prices and a variety of products such
as: Specialties Medical Center, 8 Service Centers / Opticians in
the metropolitan area, with more than 40 stores located in national
territory of Costa Rica.
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based of its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s AI-based image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024